Background The long-term trajectories of estimated glomerular filtration rate (eGFR) and their relation to early proteinuria ...
Background Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease affecting multiple organ systems, making clinical trial design challenging. Biomarkers that can identify patients ...
Original research: Telitacicept versus belimumab for the treatment of systemic lupus erythematosus: a network meta-analysis and cost-effectiveness analysis (16 January, 2026) ...
Background/Purpose SLE (Systemic Lupus Erythematosus) and SjD (Sjögren’s Disease) are similar diseases. Patients with these conditions share many overlapping features and some patients meet the ...
Haematologic involvement in patients with systemic lupus erythematosus (SLE) is very common. The principal cytopenias in lupus result in anaemia, white cell deficits and thrombocytopenia. Anaemia may ...
Background Women with systemic lupus erythematosus (SLE) historically have worse pregnancy outcomes as compared to their healthy age-matched counterparts. Auto-antibodies associated with conditions ...
LP-198 Clinical response by subgroups in patients with systemic lupus erythematosus (SLE) receiving standard of care treatment plus placebo (SOC+PBO): a post hoc analysis from clinical trial data (6 ...
Glucocorticoids represent the most potent class of anti-inflammatory drugs. However, their anti-inflammatory mode of action has been incompletely understood. Recent insights have revealed a key role ...
Lupus arthritis sometimes receives less attention than other manifestations of systemic lupus erythematosus (SLE) in routine practice and clinical trials. At a population level, however, patients ...
Introduction Cell-bound complement activation products (CB-CAPs) in a multi-analyte assay with algorithm (MAP) is a valuable biomarker for the diagnosis of SLE. Erythrocyte-bound complement activation ...
Background Mortality rates for lupus and lupus nephritis significantly vary by race/ethnicity and geographic region. Here, we examine place of death as an indirect indicator of disease outcome and ...
The heterogeneity of lupus arthritis complicates clinical management and trial endpoints. Musculoskeletal ultrasound (MSK US), and MRI have been proposed as objective assessment tools. In a systematic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results